Stroke Prevention in Atrial Fibrillation

• Author : Jan Steffel
• Publisher : Unknown
• Release : 14 August 2022

• Author : Luca Masotti,Mario Di Napoli,Daniel A. Godoy,Roberto Cappelli
• Publisher : SEEd
• Release : 05 June 2012

Cardioembolic strokes account for one third of ischemic strokes and atrial fibrillation (AF) representing the main source of this stroke subtype. The rate of stroke is 5%/year in patients with AF. Patients with AF have a 2-7 fold increased risk of stroke compared to patients without. Stroke prevention in atrial fibrillation (SPAF) is therefore of utmost importance and represents a major point in the modern management of AF. This booklet provides an overview of new oral anticoagulants used, listing their

• Author : Greg Flaker
• Publisher : Elsevier Health Sciences
• Release : 24 May 2018

Get a quick, expert overview of stroke risks among patients with treated and untreated atrial fibrillation, in addition to best practices for management and treatment of patients with atrial fibrillation to minimize stroke risks. This concise, clinically-focused resource by Dr. Greg Flaker consolidates today’s available information on this timely topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee cardiologists as well as general practitioners treating and monitoring these patients. Covers a broad spectrum

• Author : 陳柏羲
• Publisher : Unknown
• Release : 14 August 2022

• Author : Daryll M. Baker
• Publisher : Springer Science & Business Media
• Release : 10 December 2007

Primary care physicians are the first to diagnose transient ischaemic attacks (TIAs), and are the doctors who can undertake a considerable amount of stroke prevention treatment. This book fills the primary care physician’s need for a short clear text explaining how to accurately diagnose a TIA, determine what investigations are indicated and how and when to intervene to reduce the risk of stroke. Short chapters are written in point form with clear diagrams and figures, each chapter written by

• Author : Harry J. Crijns
• Publisher : Unknown
• Release : 14 August 2022

• Author : Jacqueline Saw,Saibal Kar,Matthew J. Price
• Publisher : Springer
• Release : 09 November 2015

Percutaneous left atrial appendage (LAA) closure is an emerging technology for thromboembolic prevention in patients with atrial fibrillation (AF). The first human implantation of an LAA device occurred in 2001, and since then four devices have received CE mark approval. These devices are being widely used in Europe for LAA closure in patients who are poor candidates for long-term oral anticoagulation. In the US, the WATCHMAN device (Boston Scientific) is anticipated to receive FDA approval imminently for AF patients who are

• Author : Yishen Wang
• Publisher : Unknown
• Release : 14 August 2022

• Author : Renato D. Lopes,Duke University Evidence-based Practice Center
• Publisher : Unknown
• Release : 14 August 2022

OBJECTIVES: Oral anticoagulation with vitamin K antagonists (VKAs) has long been the gold standard therapy for stroke prevention in nonvalvular atrial fibrillation (AF). Limitations in monitoring and compliance of VKAs have fueled the development of new antithrombotic strategies, devices, and oral anticoagulants, including oral direct thrombin inhibitors and factor Xa inhibitors. This review updates previous reviews, particularly with regard to these newer treatment options and the optimal risk stratification tools for stroke and bleeding prediction. DATA SOURCES: We searched PubMed(

• Author : U. S. Department Of Heal Human Services,Agency for Healthcare Resea And Quality
• Publisher : CreateSpace
• Release : 01 September 2013

Atrial fibrillation (AF) is a common type of supraventricular tachyarrhythmia. While a supraventricular tachyarrhythmia is a tachycardic rhythm originating above the ventricular tissue, AF is characterized by uncoordinated atrial activation with consequent deterioration of mechanical function. AF is the most common cardiac arrhythmia in clinical practice, accounting for approximately one-third of hospitalizations for cardiac rhythm disturbances. The estimated prevalence of AF is 0.4% to1 % in the general adult population, occurring in about 2.2 million people in the U.S. The prevalence increases

• Author : Center for Clinical Quality Evaluation
• Publisher : Unknown
• Release : 01 January 1970

• Author : Anonim
• Publisher : Unknown
• Release : 14 August 1997

• Author : Anonim
• Publisher : Unknown
• Release : 14 August 2022

• Author : John W. Norris,Vladimir Hachinski
• Publisher : Oxford University Press
• Release : 12 April 2001

The treatment of stroke remains ineffective, and prevention is the key issue for this common disease. Norris and Hachinski have recruited an international group of experts to provide a comprehensive, critical review of the evidence on the primary and secondary prevention of cerebrovascular disease and to translate this information into clinical practice. The authors present fresh information on established risk factors such as atrial fibrillation, smoking and hypertension and on new risk factors such as homocysteinemia and the paradoxical role

• Author : Anonim
• Publisher : Unknown
• Release : 14 August 1989